03.04.2012 • NewsCognisLonzaManagement

Lonza Appoints Richard Ridinger as New CEO

At a meeting on 2 April 2012, the Board of Directors of Lonza elected Richard Ridinger as the new CEO of Lonza. Mr. Ridinger, 53, will become CEO of Lonza effective 1 May. Rolf Soiron was acting CEO ad interim, since the end of January.

Richard Ridinger has held numerous leadership functions at Henkel for 14 years and Cognis for 11 years. Most recently, Mr. Ridinger was responsible for Care Chemicals, the largest sector at Cognis with approximately 3,000 employees. During his tenure, sales increased by 60% to €1.75 billion over six years, as he successfully repositioned the business in the market.

At the 2 April meeting, the Board of Directors also appointed Marc Funk, Group General Counsel and Board Secretary, to become a member of the Management Committee. Marc Funk joined Lonza in January 2009; prior he was associate general counsel at Merck Serono.

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.